Victory Capital Management Inc. Has $66.21 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Victory Capital Management Inc. raised its holdings in Zoetis Inc. (NYSE:ZTS) by 8.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 338,866 shares of the company’s stock after purchasing an additional 26,789 shares during the quarter. Victory Capital Management Inc. owned 0.07% of Zoetis worth $66,208,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ZTS. First Personal Financial Services acquired a new position in Zoetis during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis during the third quarter worth $33,000. Quarry LP increased its holdings in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares in the last quarter. LRI Investments LLC bought a new position in shares of Zoetis in the 1st quarter valued at $43,000. Finally, Fortitude Family Office LLC boosted its holdings in shares of Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after acquiring an additional 222 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ZTS. BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. boosted their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Trading Down 1.4 %

ZTS opened at $174.63 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a fifty day moving average of $187.61 and a 200-day moving average of $180.02. The stock has a market cap of $78.79 billion, a PE ratio of 32.83, a price-to-earnings-growth ratio of 2.67 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s revenue was up 11.6% compared to the same quarter last year. During the same period last year, the business posted $1.36 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.99%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 32.33%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.